# OnCo record epi-326 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/epi-326/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "epi-326" ;
  schema:name "EPI-326"@en ;
  schema:description "EPI-326 is an experimental bispecific antibody degrader from EpiBiologics, in phase 1 trials for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma."@en ;
  schema:url <https://onco.cc/drugs/epi-326/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.epibiologics.com/pipeline>, <https://www.epibiologics.com/pipeline>, <https://clinicaltrials.gov/study/NCT07462377>, <https://clinicaltrials.gov/search?intr=EPI-326> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific antibody degrader (EpiTAC)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/epibiologics/> ;
  onco:trials <https://onco.cc/trials/nct07462377/> .